French pharmaceutical company Sanofi announced Tuesday that it was halting clinical trials of its drug Kevzara for use against the novel coronavirus.
Recent international clinical trials conducted with the drug -- typically used for rheumatoid arthritis -- have produced adverse reactions in some patients, including pneumonia and even death.
Sanofi is one of several companies currently attempting to develop a vaccine against COVID-19. It manufactures Kevzara with its American partner Regeneron.
John Reed, Sanofi's global head of research and development, expressed appreciation for his team's efforts in testing the drug.
"Although this trial did not yield the results we hoped for, we are proud of the work that was achieved by the team to further our understanding of the potential use of Kevzara for the treatment of COVID-19," he said in a statement to Radio France International.
Exactly one month ago, the European Commission promised to buy 300 million doses of a potential vaccine developed by Sanofi. As part of that pledge, all 27 EU member countries could also have separately purchased amounts of the vaccine.
On the same day, the US also promised $2.1 billion to Sanofi and British pharmaceutical GlaxoSmithKline (GSK) for the development of a vaccine.
Previously, Russia announced in August that its scientists had developed a vaccine that successfully combated the virus. Although approved by Russian health authorities, the drug had not been put through phase III clinical trials necessary to prove the efficacy and safety of its use.
The coronavirus pandemic has claimed more than 851,000 lives in 188 countries and regions since originating in China last December. The US, Brazil, India, and Russia are currently the worst-hit countries.
Over 25.5 million COVID-19 cases have been reported worldwide, with recoveries exceeding 16.8 million, according to figures compiled by the US-based Johns Hopkins University.
See all the news
Franco Frattini - Georgia, straying from the rule of law
Letter to the Newsweek Editor: 'Russia Determined to Wield Power in Georgia'
Caspiannews: Georgia’s Actions to Seize Foreign Company Disrupt Telecommunications Corridor Between Europe & Asia
Turkish cable manufacturer Koc Kablo has opened its first factory in Georgia
TBC Bank announces management change
Oil prices fall further on virus fears, U.S. crude stock build
Update on Shuakhevi HPP
Turkey to open doors to 31 countries for health tourism
Statement by Andrius Kubilius on the EU assistance for Georgia
Wine sales have increased 5 times in the UK - Georgian-British startup
Visa informed banks of the mechanism to process transactions with expired cards
Russian Church, which priest tested positive for coronavirus is closed for several days
S&P: Georgia Heads Toward Recession
Gurian Tea "Gamarjoba" will Appear on the Market from September
Coronavirus: Boris Johnson moved to intensive care
First-Stage Land Usage Permit for APM Terminals Poti
www.stopcov.ge is accessible in minority languages
TBC Bank and OPEC Fund sign a $50 million trade finance loan agreement
How will Nenskra HPP Reduce the Electricity Import?
JSC Nenskra Hydro Shifts to Remote Work